Iovance Biotherapeutics, Inc.

NasdaqGM:IOVA Stock Report

Market Cap: US$3.4b

Iovance Biotherapeutics Management

Management criteria checks 4/4

Iovance Biotherapeutics' CEO is Frederick Vogt, appointed in Jul 2017, has a tenure of 7.33 years. total yearly compensation is $4.79M, comprised of 14.4% salary and 85.6% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth $2.29M. The average tenure of the management team and the board of directors is 3.7 years and 7.5 years respectively.

Key information

Frederick Vogt

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage14.4%
CEO tenure7.3yrs
CEO ownership0.07%
Management average tenure3.7yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Iovance Biotherapeutics: Moving To The Next Phase

Oct 03

Iovance Therapeutics: Historic Product, Tough Commercial Outlook

Sep 06

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Aug 11

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Jun 26

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Aug 25
Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Aug 04

Iovance: TIL Cell Therapy Set To Prove Itself

Jul 11

Iovance: Onward To Approval

Apr 20

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

CEO Compensation Analysis

How has Frederick Vogt's remuneration changed compared to Iovance Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$440m

Mar 31 2024n/an/a

-US$450m

Dec 31 2023US$5mUS$692k

-US$444m

Sep 30 2023n/an/a

-US$433m

Jun 30 2023n/an/a

-US$419m

Mar 31 2023n/an/a

-US$412m

Dec 31 2022US$5mUS$650k

-US$396m

Sep 30 2022n/an/a

-US$390m

Jun 30 2022n/an/a

-US$376m

Mar 31 2022n/an/a

-US$358m

Dec 31 2021US$8mUS$471k

-US$342m

Sep 30 2021n/an/a

-US$311m

Jun 30 2021n/an/a

-US$284m

Mar 31 2021n/an/a

-US$265m

Dec 31 2020US$3mUS$418k

-US$260m

Sep 30 2020n/an/a

-US$255m

Jun 30 2020n/an/a

-US$246m

Mar 31 2020n/an/a

-US$230m

Dec 31 2019US$2mUS$398k

-US$198m

Sep 30 2019n/an/a

-US$167m

Jun 30 2019n/an/a

-US$151m

Mar 31 2019n/an/a

-US$134m

Dec 31 2018US$514kUS$375k

-US$124m

Sep 30 2018n/an/a

-US$117m

Jun 30 2018n/an/a

-US$105m

Mar 31 2018n/an/a

-US$98m

Dec 31 2017US$860kUS$326k

-US$92m

Compensation vs Market: Frederick's total compensation ($USD4.79M) is about average for companies of similar size in the US market ($USD6.66M).

Compensation vs Earnings: Frederick's compensation has been consistent with company performance over the past year.

CEO

Frederick Vogt (50 yo)

7.3yrs

Tenure

US$4,794,680

Compensation

Dr. Frederick G. Vogt, PhD, Esq., JD, serves as an Interim CEO & President at Iovance Biotherapeutics, Inc. since June 19, 2021 and is its Director since June 11, 2024. He has been the General Counsel at I...

Leadership Team

NamePositionTenureCompensationOwnership
Frederick Vogt
Interim CEO7.3yrsUS$4.79m0.067%
$ 2.3m
Jean-Marc Bellemin
CFO, Principal Accounting Officer & Treasurer3.9yrsUS$1.71m0.0097%
$ 328.4k
Igor Bilinsky
Chief Operating Officer3.7yrsUS$1.59m0.018%
$ 624.6k
Friedrich Graf Finckenstein
Chief Medical Officer5.3yrsUS$1.77m0.020%
$ 679.6k
Sara Pellegrino
Vice President of Investor Relations & Public Relationsno datano datano data
Tracy Winton
Executive Vice President of Human Resources2.6yrsno datano data
Howard Johnson
Chief Business Officer5.7yrsno datano data
Raj Puri
Executive VP of Regulatory Strategy & Translational Medicine2.7yrsno datano data
Brian Shew
Senior VP & Head of Digital and Information Technology2.6yrsno datano data
Kevin Smyth
Executive Vice President of Quality3.8yrsno datano data
Hequn Yin
Senior Vice President of Research2.6yrsno datano data
Brian Gastman
Executive Vice President of Medical Affairs1.3yrsno datano data

3.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: IOVA's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frederick Vogt
Interim CEOless than a yearUS$4.79m0.067%
$ 2.3m
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
Wayne Rothbaum
Independent Director8.4yrsUS$240.00k9.25%
$ 314.1m
Michael Weiser
Independent Director6.7yrsUS$744.99k0.046%
$ 1.6m
Jeffrey Weber
Member of Scientific Advisory Boardno datano datano data
Patrick Hwu
Member of Scientific Advisory Boardno datano datano data
Ryan Maynard
Independent Director9.8yrsUS$489.99k0.0025%
$ 83.9k
Iain Dukes
Independent Chairman of the Board8.3yrsUS$933.48k0.018%
$ 604.2k
James Mule
Member of Scientific Advisory Boardno datano datano data
Athena Countouriotis
Independent Director5.4yrsUS$489.99k0%
$ 0
Cassian Yee
Member of Scientific Advisory Boardno datano datano data
Daniel Powell
Member of Scientific Advisory Boardno datano datano data

7.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: IOVA's board of directors are considered experienced (7.5 years average tenure).